CASI PHARMACEUTICALS, INC. (CASIF) Gross margin 2020–2025
CASI PHARMACEUTICALS, INC. (CASIF) gross margin by fiscal year — reported gross profit divided by reported revenue.
48.6%FY2025 · since FY2020: 37.6% → 48.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 48.6% | +9.6 pp |
| FY2024 | 39.1% | -20.1 pp |
| FY2023 | 59.2% | -12.5 pp |
| FY2022 | 71.7% | +13.0 pp |
| FY2021 | 58.7% | +21.1 pp |
| FY2020 | 37.6% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More CASIF financial trends
CASIF RevenueCASIF Net incomeCASIF Net marginCASIF Gross profitCASIF Operating incomeCASIF Operating marginCASIF Operating cash flowCASIF Free cash flowCASIF Capital expendituresCASIF Return on equityCASIF Stock buybacksCASIF Dividends paidCASIF Total assetsCASIF Total liabilitiesCASIF Shareholders’ equityCASIF overview →